Which has stronger valuation and earnings, LIVN or BVS?

Bioventus has lower revenue, but higher earnings than LivaNova. Bioventus is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 3.22 -$242.47M $3.38 24.02 Bioventus $568.09M 2.13 $22.73M $0.77 18.65

Is LIVN or BVS more profitable?

LivaNova has a net margin of 12.82% compared to Bioventus' net margin of 9.36%. Bioventus' return on equity of 28.08% beat LivaNova's return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 12.82% 16.35% 7.76% Bioventus 9.36% 28.08% 9.82%

Does the media prefer LIVN or BVS?

In the previous week, LivaNova had 4 more articles in the media than Bioventus. MarketBeat recorded 5 mentions for LivaNova and 1 mentions for Bioventus. Bioventus' average media sentiment score of 1.02 beat LivaNova's score of 0.88 indicating that Bioventus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, BVS or ITGR?

Integer has higher revenue and earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $568.09M 2.13 $22.73M $0.77 18.65 Integer $1.85B 2.30 $102.81M $3.66 34.30

Is BVS or ITGR more profitable?

Bioventus has a net margin of 9.36% compared to Integer's net margin of 6.97%. Bioventus' return on equity of 28.08% beat Integer's return on equity. Company Net Margins Return on Equity Return on Assets Bioventus 9.36% 28.08% 9.82% Integer 6.97% 12.79% 6.48%

Does the media refer more to BVS or ITGR?

In the previous week, Integer had 10 more articles in the media than Bioventus. MarketBeat recorded 11 mentions for Integer and 1 mentions for Bioventus. Integer's average media sentiment score of 1.09 beat Bioventus' score of 1.02 indicating that Integer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Integer 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IRTC or BVS?

In the previous week, iRhythm Technologies had 1 more articles in the media than Bioventus. MarketBeat recorded 2 mentions for iRhythm Technologies and 1 mentions for Bioventus. Bioventus' average media sentiment score of 1.02 beat iRhythm Technologies' score of 0.88 indicating that Bioventus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRhythm Technologies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, PLSE or BVS?

Bioventus has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulse Biosciences $350K 10,818.51 -$72.78M -$1.18 N/A Bioventus $568.09M 2.13 $22.73M $0.77 18.65

Does the media favor PLSE or BVS?

In the previous week, Pulse Biosciences had 17 more articles in the media than Bioventus. MarketBeat recorded 18 mentions for Pulse Biosciences and 1 mentions for Bioventus. Pulse Biosciences' average media sentiment score of 1.27 beat Bioventus' score of 1.02 indicating that Pulse Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, TMDX or BVS?

TransMedics Group has higher revenue and earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransMedics Group $605.49M 4.96 $190.29M $3.89 22.36 Bioventus $568.09M 2.13 $22.73M $0.77 18.65

Does the media prefer TMDX or BVS?

In the previous week, TransMedics Group had 10 more articles in the media than Bioventus. MarketBeat recorded 11 mentions for TransMedics Group and 1 mentions for Bioventus. Bioventus' average media sentiment score of 1.02 beat TransMedics Group's score of 0.95 indicating that Bioventus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 6 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Bioventus (BVS) Competitors

$14.36 -0.01 (-0.07%)

As of 09/3/2026 04:00 PM Eastern

Compare

BVS vs. LIVN, ITGR, IRTC, PLSE, and TMDX

Should you buy Bioventus stock or one of its competitors? Bioventus's main competitors and comparable companies include LivaNova (LIVN), Integer (ITGR), iRhythm Technologies (IRTC), Pulse Biosciences (PLSE), and TransMedics Group (TMDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Bioventus compare to LivaNova?

LivaNova (NASDAQ:LIVN) and Bioventus (NASDAQ:BVS) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

Bioventus has lower revenue, but higher earnings than LivaNova. Bioventus is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.22	-$242.47M	$3.38	24.02
Bioventus	$568.09M	2.13	$22.73M	$0.77	18.65

In the previous week, LivaNova had 4 more articles in the media than Bioventus. MarketBeat recorded 5 mentions for LivaNova and 1 mentions for Bioventus. Bioventus' average media sentiment score of 1.02 beat LivaNova's score of 0.88 indicating that Bioventus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bioventus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LivaNova has a net margin of 12.82% compared to Bioventus' net margin of 9.36%. Bioventus' return on equity of 28.08% beat LivaNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	12.82%	16.35%	7.76%
Bioventus	9.36%	28.08%	9.82%

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 62.9% of Bioventus shares are owned by institutional investors. 0.4% of LivaNova shares are owned by company insiders. Comparatively, 33.5% of Bioventus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

LivaNova has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, Bioventus has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

LivaNova presently has a consensus target price of $84.13, suggesting a potential upside of 3.60%. Bioventus has a consensus target price of $16.80, suggesting a potential upside of 16.99%. Given Bioventus' stronger consensus rating and higher possible upside, analysts plainly believe Bioventus is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55
Bioventus	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

LivaNova beats Bioventus on 9 of the 16 factors compared between the two stocks.

How does Bioventus compare to Integer?

Bioventus (NASDAQ:BVS) and Integer (NYSE:ITGR) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

Bioventus currently has a consensus price target of $16.80, indicating a potential upside of 16.99%. Integer has a consensus price target of $109.86, indicating a potential downside of 12.49%. Given Bioventus' stronger consensus rating and higher possible upside, equities analysts clearly believe Bioventus is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07

Integer has higher revenue and earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	2.13	$22.73M	$0.77	18.65
Integer	$1.85B	2.30	$102.81M	$3.66	34.30

Bioventus has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, Integer has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

62.9% of Bioventus shares are owned by institutional investors. Comparatively, 99.3% of Integer shares are owned by institutional investors. 33.5% of Bioventus shares are owned by company insiders. Comparatively, 1.1% of Integer shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Integer had 10 more articles in the media than Bioventus. MarketBeat recorded 11 mentions for Integer and 1 mentions for Bioventus. Integer's average media sentiment score of 1.09 beat Bioventus' score of 1.02 indicating that Integer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Integer	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bioventus has a net margin of 9.36% compared to Integer's net margin of 6.97%. Bioventus' return on equity of 28.08% beat Integer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	9.36%	28.08%	9.82%
Integer	6.97%	12.79%	6.48%

Summary

Bioventus and Integer tied by winning 8 of the 16 factors compared between the two stocks.

How does Bioventus compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and Bioventus (NASDAQ:BVS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

62.9% of Bioventus shares are held by institutional investors. 1.0% of iRhythm Technologies shares are held by insiders. Comparatively, 33.5% of Bioventus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Bioventus has lower revenue, but higher earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	5.45	-$44.55M	-$0.43	N/A
Bioventus	$568.09M	2.13	$22.73M	$0.77	18.65

In the previous week, iRhythm Technologies had 1 more articles in the media than Bioventus. MarketBeat recorded 2 mentions for iRhythm Technologies and 1 mentions for Bioventus. Bioventus' average media sentiment score of 1.02 beat iRhythm Technologies' score of 0.88 indicating that Bioventus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bioventus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bioventus has a net margin of 9.36% compared to iRhythm Technologies' net margin of -1.69%. Bioventus' return on equity of 28.08% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-1.69%	10.11%	1.53%
Bioventus	9.36%	28.08%	9.82%

iRhythm Technologies currently has a consensus target price of $179.93, indicating a potential upside of 45.77%. Bioventus has a consensus target price of $16.80, indicating a potential upside of 16.99%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe iRhythm Technologies is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
Bioventus	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

iRhythm Technologies has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market. Comparatively, Bioventus has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market.

Summary

Bioventus beats iRhythm Technologies on 9 of the 17 factors compared between the two stocks.

How does Bioventus compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and Bioventus (NASDAQ:BVS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Pulse Biosciences presently has a consensus target price of $45.25, suggesting a potential downside of 17.29%. Bioventus has a consensus target price of $16.80, suggesting a potential upside of 16.99%. Given Bioventus' stronger consensus rating and higher probable upside, analysts clearly believe Bioventus is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Bioventus	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Bioventus has a net margin of 9.36% compared to Pulse Biosciences' net margin of -6,755.78%. Bioventus' return on equity of 28.08% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%
Bioventus	9.36%	28.08%	9.82%

Bioventus has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	10,818.51	-$72.78M	-$1.18	N/A
Bioventus	$568.09M	2.13	$22.73M	$0.77	18.65

77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 62.9% of Bioventus shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by insiders. Comparatively, 33.5% of Bioventus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Pulse Biosciences has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market. Comparatively, Bioventus has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

In the previous week, Pulse Biosciences had 17 more articles in the media than Bioventus. MarketBeat recorded 18 mentions for Pulse Biosciences and 1 mentions for Bioventus. Pulse Biosciences' average media sentiment score of 1.27 beat Bioventus' score of 1.02 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bioventus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bioventus beats Pulse Biosciences on 10 of the 16 factors compared between the two stocks.

How does Bioventus compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and Bioventus (NASDAQ:BVS) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

TransMedics Group has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market. Comparatively, Bioventus has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

In the previous week, TransMedics Group had 10 more articles in the media than Bioventus. MarketBeat recorded 11 mentions for TransMedics Group and 1 mentions for Bioventus. Bioventus' average media sentiment score of 1.02 beat TransMedics Group's score of 0.95 indicating that Bioventus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	6 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bioventus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TransMedics Group currently has a consensus target price of $124.18, suggesting a potential upside of 42.77%. Bioventus has a consensus target price of $16.80, suggesting a potential upside of 16.99%. Given TransMedics Group's higher possible upside, equities research analysts plainly believe TransMedics Group is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38
Bioventus	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

TransMedics Group has a net margin of 22.69% compared to Bioventus' net margin of 9.36%. Bioventus' return on equity of 28.08% beat TransMedics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	22.69%	15.88%	5.95%
Bioventus	9.36%	28.08%	9.82%

TransMedics Group has higher revenue and earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	4.96	$190.29M	$3.89	22.36
Bioventus	$568.09M	2.13	$22.73M	$0.77	18.65

99.7% of TransMedics Group shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 6.9% of TransMedics Group shares are held by insiders. Comparatively, 33.5% of Bioventus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

TransMedics Group beats Bioventus on 11 of the 16 factors compared between the two stocks.

Get Bioventus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BVS vs. The Competition

Export

Metric	Bioventus	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.21B	$5.81B	$7.26B	$12.73B
Dividend Yield	N/A	1.76%	2.53%	8.86%
P/E Ratio	18.65	25.93	273.28	25.38
Price / Sales	2.13	73.29	613.48	92.60
Price / Cash	11.27	33.14	77.82	52.26
Price / Book	4.35	6.04	12.89	6.14
Net Income	$22.73M	$150.03M	$3.47B	$349.01M
7 Day Performance	3.76%	-1.30%	0.61%	-0.27%
1 Month Performance	7.00%	1.29%	5.73%	0.68%
1 Year Performance	102.25%	9.89%	25.37%	14.84%

Bioventus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BVS Bioventus	4.4517 of 5 stars	$14.36 -0.1%	$16.80 +17.0%	+104.0%	$1.21B	$568.09M	18.65	1,200
LIVN LivaNova	2.5556 of 5 stars	$80.32 +0.4%	$83.50 +4.0%	+43.5%	$4.41B	$1.39B	23.76	3,300	Analyst Forecast Insider Trade
ITGR Integer	2.9962 of 5 stars	$125.30 flat	$109.86 -12.3%	+18.7%	$4.26B	$1.84B	34.24	11,000	Positive News
IRTC iRhythm Technologies	4.0256 of 5 stars	$120.25 +3.4%	$179.93 +49.6%	-30.1%	$3.83B	$747.14M	N/A	2,400	Positive News
PLSE Pulse Biosciences	2.1399 of 5 stars	$47.57 -2.0%	$45.25 -4.9%	+265.0%	$3.29B	$1.19M	N/A	140	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BVS) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bioventus (BVS) Competitors

BVS vs. LIVN, ITGR, IRTC, PLSE, and TMDX

How does Bioventus compare to LivaNova?

Summary

How does Bioventus compare to Integer?

Summary

How does Bioventus compare to iRhythm Technologies?

Summary

How does Bioventus compare to Pulse Biosciences?

Summary

How does Bioventus compare to TransMedics Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVS vs. The Competition

Bioventus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bioventus (BVS) Competitors

BVS vs. LIVN, ITGR, IRTC, PLSE, and TMDX

How does Bioventus compare to LivaNova?

Which has stronger valuation and earnings, LIVN or BVS?

Does the media prefer LIVN or BVS?

Is LIVN or BVS more profitable?

Do insiders & institutionals hold more shares of LIVN or BVS?

Which has more volatility & risk, LIVN or BVS?

Do analysts recommend LIVN or BVS?

Summary

How does Bioventus compare to Integer?

Do analysts rate BVS or ITGR?

Which has preferable valuation & earnings, BVS or ITGR?

Which has more volatility & risk, BVS or ITGR?

Do insiders and institutionals have more ownership in BVS or ITGR?

Does the media refer more to BVS or ITGR?

Is BVS or ITGR more profitable?

Summary

How does Bioventus compare to iRhythm Technologies?

Do institutionals & insiders have more ownership in IRTC or BVS?

Which has preferable valuation and earnings, IRTC or BVS?

Does the media favor IRTC or BVS?

Is IRTC or BVS more profitable?

Do analysts prefer IRTC or BVS?

Which has more volatility & risk, IRTC or BVS?

Summary

How does Bioventus compare to Pulse Biosciences?

Do analysts recommend PLSE or BVS?

Is PLSE or BVS more profitable?

Which has higher valuation and earnings, PLSE or BVS?

Do institutionals and insiders hold more shares of PLSE or BVS?

Which has more risk & volatility, PLSE or BVS?

Does the media favor PLSE or BVS?

Summary

How does Bioventus compare to TransMedics Group?

Which has more volatility & risk, TMDX or BVS?

Does the media prefer TMDX or BVS?

Do analysts recommend TMDX or BVS?

Is TMDX or BVS more profitable?

Which has higher valuation and earnings, TMDX or BVS?

Do institutionals & insiders have more ownership in TMDX or BVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVS vs. The Competition

Bioventus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools